

ischemic heart disease, the pharmaceutical composition comprising a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has an effect of reducing an infarct region.

REMARKS


By the present Preliminary Amendment, applicant has amended the specification to add the headings suggested by the U.S. Patent and Trademark Office. In addition, the Sequence Listing on pages 12-16 has been deleted because a Sequence Listing believed to be in compliance with 37 C.F.R. §§ 1.821-1.825 was submitted with the application. Further, claim 1 has also been amended solely for clarification purposes to conform to the U.S. practice. No new matter is added. In accordance with 37 C.F.R. § 1.121, a marked up version of the amended specification and claim 1 is attached.

Entry of the foregoing and prompt and favorable consideration of the subject application on the merits are respectfully requested.

Respectfully submitted,

Date: March 12, 2001

By:



Robert M. Schulman, Reg. No. 31,196
Paul D. Golian, Reg. No. 42,591

Hunton & Williams
1900 K Street, NW, Suite 1200
Washington, D.C. 20006-1109
Telephone: (202) 955-1500
Facsimile: (202) 778-2201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT Application of:)	
)	
Masafumi KITAKAZE)	Group Art Unit: Not yet assigned
)	
Serial No. 09/752,724)	Examiner: Not yet assigned
)	
Filed: January 3, 2001)	

For: TREATMENT OR PROPHYLAXIS OF ISCHEMIC HEART DISEASE

**MARKED UP VERSION OF REPLACEMENT SECTION HEADING AND
REWRITTEN CLAIM ACCOMPANYING PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the present Preliminary Amendment, the section heading at page 1, line 3, and claim 1 have been amended. In accordance with 37 C.F.R. § 1.121, a marked up version is provided.

IN THE SPECIFICATION:

At page 1, line 3:

[BACKGROUND OF THE INVENTION] Field of the Invention

IN THE CLAIMS:


1. "amended" A pharmaceutical composition for use in treatment or prophylaxis of ischemic heart disease, the pharmaceutical composition [containing] comprising a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has an effect of reducing an infarct region.

In the event that there are questions relating to this submission, it would be appreciated if the Examiner would contact the undersigned attorneys concerning such questions.

Respectfully submitted,

Date: March 12, 2001

By:


Robert M. Schulman, Reg. No. 31,196
Paul D. Golian, Reg. No. 42,591

Hunton & Williams
1900 K Street, NW, Suite 1200
Washington, D.C. 20006-1109
Telephone: (202) 955-1500
Facsimile: (202) 778-2201